- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03680508
TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) in Patients With Liver Cancer
Phase II Study of TSR-022 (Cobolimab) in Combination With TSR-042 (Dostarlimab) for the Treatment of Advanced Hepatocellular Carcinoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. To assess the objective response rate (ORR) as determined by RECIST v1.1 of advanced hepatocellular cancer (HCC) patients treated with TSR-022 (cobolimab, TIM-3 binding antibody) and TSR-042 (dostarlimab, PD-1 binding antibody).
SECONDARY OBJECTIVES:
I. To determine the ORR as determined by the immune related Response Criteria (irRC), duration of response (DOR), time to progression (TTP), progression free survival (PFS), overall survival (OS), and alpha-fetoprotein (AFP) response of study participants.
II. To evaluate the safety profile of treated patients.
OUTLINE:
Patients receive TSR-022 (cobolimab, TIM-3 binding antibody) and TSR-042 (dostarlimab, PD-1 binding antibody) on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Patients are followed every 9 weeks.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Jared D Acoba, MD
- Phone Number: 8085318521
- Email: jacoba@hawaii.edu
Study Contact Backup
- Name: Jill Drucker, MS
- Phone Number: 8085643989
- Email: IIT@cc.hawaii.edu
Study Locations
-
-
Hawaii
-
Honolulu, Hawaii, United States, 96813
- Recruiting
- University of Hawaii
-
Contact:
- Jared D Acoba, MD
- Phone Number: 808-531-8521
- Email: jacoba@hawaii.edu
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Recruiting
- Oregon Health & Science University Knight Cancer Institute
-
Contact:
- Adel Kardosh, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Histologically or cytologically confirmed hepatocellular cancer
- Barcelona Clinic Liver Cancer Stage B or C
- Cirrhosis grade of Child-Pugh class A or B7
- Subjects with HBV infection are required to be receiving effective antiviral therapy and have a viral load less than 100 IU/mL. Antiviral therapy is not required for subjects with HCV infection
- Have at least one tumor lesion that can be accurately measured according to Response Evaluation Criteria in Solid Tumor (RECIST v1.1)
- No prior systemic therapy for HCC
- Age ≥ 18 years
- ECOG performance status 0-1
- Resolved acute effects of any prior therapy to baseline or Grade ≤1 NCI CTCAE
- Have adequate hematologic function as documented by ANC ≥ 1000/μcl, platelet count ≥ 60,000/μcl, and hemoglobin ≥ 8.5 mg/dl
- Have adequate renal function as determined by a measured or calculated creatinine clearance ≥ 40 mL/min using the Cockcroft-Gault formula
- Have adequate hepatic function, as documented by ALT and AST ≤5x upper limit of normal, total bilirubin ≤3 mg/dL, and albumin ≥2.8 g/dL
- International normalized ratio (INR) or prothrombin time (PT) ≤2× ULN unless patient is receiving anticoagulant therapy as long as PT or partial thromboplastin (PTT) is within therapeutic range of intended use of anticoagulants
- Prior local therapy, such as surgery, radioembolization, chemoembolization, or radiofrequency ablation is allowed if the index lesion(s) remains outside of the treatment field or has progressed since prior treatment
- Participants must agree to not donate blood during the study or for 90 days after the last dose of protocol therapy
- Female participant has a negative urine or serum pregnancy test within 7 days prior to taking study treatment if of childbearing potential and agrees to abstain from activities that could result in pregnancy from screening through 180 days after the last dose of study treatment, or is of nonchildbearing potential.
- Participant must be able to understand the study procedures and agree to participate in the study by providing written informed consent.
Exclusion Criteria:
- Participant must not be simultaneously enrolled in any interventional clinical trial
- Participant must not have had major surgery ≤ 3 weeks prior to initiating protocol therapy and participant must have recovered from any surgical effects
- Participants must not have received investigational therapy ≤4 weeks, or within a time interval less than at least 5 half-lives of the investigational agent, whichever is shorter, prior to initiating protocol therapy.
- Active or untreated central nervous system (CNS) and leptomeningeal metastases are excluded
- Prior therapy with any medication targeting PD-1, PD-L1, or TIM-3
- Participant must not have a known hypersensitivity to TSR-042 and TSR-022 components or excipients.
- Participants with active malignancy (other than HCC) or a prior malignancy within the past 2 years are excluded. Participants with completely resected cutaneous melanoma (early stage), basal cell carcinoma, cutaneous squamous cell carcinoma, cervical carcinoma in-situ, breast carcinoma in-situ, and localized prostate cancer are eligible
- Participant must not have serious, uncontrolled medical disorder, or nonmalignant systemic disease. Examples include, but are not limited to uncontrolled ventricular arrhythmia, uncontrolled major seizure disorder, unstable spinal cord compression, or superior vena cava syndrome.
- Unstable angina, new onset angina within last 3 months, myocardial infarction within last 6 months and current congestive heart failure New York Heart Association Class II or higher
- Known history of Human Immunodeficiency Virus (HIV) infection
- Active tuberculosis infection or other microbial infection or any active systemic infection requiring parenteral antibiotic therapy. All prior infections must have resolved following optimal therapy.
- Participant has an active autoimmune disease that has required systemic treatment in the past 2 years (.ie., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
- History of idiopathic pulmonary fibrosis, interstitial lung disease, bronchial asthma, organizing pneumonia, bronchiolitis obliterans, drug-induced pneumonitis, or idiopathic pneumonitis
- History of organ transplantation including allogeneic bone marrow transplantation
- Participant has a diagnosis of immunodeficiency or has receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to initiating protocol therapy.
- Participant has received a live vaccine within 7 days of initiating protocol therapy.
- Psychiatric illness/social situations that would limit compliance with study requirements
- Pregnant, lactating, breastfeeding, or intending to become pregnant during the study and for 180 days after the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TSR-022 (Cobolimab) and TSR-042 (Dostarlimab)
Patients receive TSR-022 (cobolimab, TIM-3 binding antibody) and TSR-042 (dostarlimab, PD-1 binding antibody) via IV day 1.
Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
|
immunotherapy
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate
Time Frame: From date of treatment until the date of best documented response, assessed up to 36 months
|
Determined by RECIST v1.1 criteria
|
From date of treatment until the date of best documented response, assessed up to 36 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate (irRC)
Time Frame: From date of treatment until the date of best documented response, assessed up to 36 months
|
Objective response as determined by the immune related Response Criteria
|
From date of treatment until the date of best documented response, assessed up to 36 months
|
Duration of Response
Time Frame: From date of treatment until the date of progression, assessed up to 36 months
|
Time from tumor response to progression
|
From date of treatment until the date of progression, assessed up to 36 months
|
Time to progression
Time Frame: From date of treatment until the date of progression, assessed up to 36 months
|
Time from treatment to progression of cancer
|
From date of treatment until the date of progression, assessed up to 36 months
|
Progression free survival
Time Frame: From date of treatment until the date of progression or death, assessed up to 36 months
|
Time from treatment to progression of cancer or death
|
From date of treatment until the date of progression or death, assessed up to 36 months
|
Overall survival
Time Frame: From date of treatment until the date of death, assessed up to 36 months
|
Time from treatment to death
|
From date of treatment until the date of death, assessed up to 36 months
|
AFP response
Time Frame: From treatment start to documentation of AFP progression, assessed up to 36 months.
|
Percentage of AFP decrease from baseline to nadir
|
From treatment start to documentation of AFP progression, assessed up to 36 months.
|
Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v4.0
Time Frame: From treatment until cessation of study treatment and resolution of adverse events, assessed up to 36 months
|
Tabulation of adverse events, CTCAE v4.0
|
From treatment until cessation of study treatment and resolution of adverse events, assessed up to 36 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Jared D Acoba, MD, University of Hawaii
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ACOBA-2017-2
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Adult Primary Liver Cancer
-
University of CincinnatiActive, not recruitingLiver Metastases | Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver CancerUnited States
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)TerminatedAdvanced Adult Primary Liver Cancer | Localized Resectable Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Adult Primary Hepatocellular Carcinoma | Stage A Adult Primary Liver Cancer (BCLC) | Stage B Adult Primary Liver Cancer (BCLC)United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedAdvanced Adult Primary Liver Cancer | Localized Resectable Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Adult Primary Hepatocellular CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedAdvanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Adult Primary Hepatocellular CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedAdvanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Adult Primary Hepatocellular CarcinomaUnited States
-
Ohio State University Comprehensive Cancer CenterCompletedAdvanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Adult Primary Hepatocellular CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedAdvanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Adult Primary Hepatocellular CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedAdvanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Adult Primary Hepatocellular CarcinomaUnited States, Singapore
-
University of WashingtonNational Cancer Institute (NCI)TerminatedAdvanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Adult Primary Hepatocellular CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedAdvanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Adult Primary Hepatocellular CarcinomaUnited States
Clinical Trials on TSR-022 and TSR-042
-
Diwakar DavarTesaro, Inc.RecruitingMelanoma Stage IV | Melanoma Stage IIIUnited States
-
Meghan SheaGlaxoSmithKlineRecruitingCervical Cancer | Recurrent Cervical Carcinoma | Metastatic Cervical Cancer | Metastatic Cervical Carcinoma | Advanced Cervical CarcinomaUnited States
-
Tesaro, Inc.RecruitingNeoplasmsUnited States, Spain
-
Grupo Español de Investigación en Cáncer de OvarioApices Soluciones S.L.; TESARO/GSKActive, not recruitingCervical Cancer | Advanced CancerSpain, Turkey
-
Italian Sarcoma GroupGlaxoSmithKlineTerminated
-
University of IowaRecruitingColon Cancer | dMMR Colorectal CancerUnited States
-
GlaxoSmithKlineRecruitingNeoplasmsUnited States, Spain, Korea, Republic of
-
NYU Langone HealthActive, not recruiting
-
Memorial Sloan Kettering Cancer CenterTesaro, Inc.Active, not recruitingEndometrial CancerUnited States
-
GlaxoSmithKlineRecruitingNeoplasms, RectalUnited States, France, Italy, Japan, Spain, United Kingdom, Germany, Korea, Republic of, Canada, Netherlands